Vinh DC, Rubinstein E (2009) Linezolid: a review of safety and tolerability. J Infect 59(Suppl 1):S59-74

Article  PubMed  Google Scholar 

Dresser LD, Rybak MJ (1998) The pharmacologic and bacteriologic properties of oxazolidinones, a new class of synthetic antimicrobials. Pharmacotherapy 18(3):456–462

Article  CAS  PubMed  Google Scholar 

Stalker DJ, Jungbluth GL (2003) Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin Pharmacokinet 42:1129–1140

Article  CAS  PubMed  Google Scholar 

World Health Organization (2022) Antimicrobial resistance. Global antimicrobial resistance and use surveillance system (GLASS) report. WHO. Available from: https://www.who.int/en/news-room/fact-sheets/detail/antimicrobial-resistance. Accessed 17 Mar 2024

Almutairi H, Albahadel H, Alhifany A et al (2024) Prevalence and antimicrobial susceptibility pattern of methicillin-resistant Staphylococcus aureus (MRSA) at a maternity and children hospital in Saudi Arabia: A cross-sectional study. Saudi Pharm J 32(4):102001

Article  CAS  PubMed  PubMed Central  Google Scholar 

Banawas SS, Alobaidi AS, Dawoud TM et al (2023) Prevalence of multidrug-resistant bacteria in healthcare-associated bloodstream infections at hospitals in Riyadh, Saudi Arabia. Pathogens 12(9):1075

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fang P, Gao K, Yang J et al (2023) Prevalence of multidrug-resistant pathogens causing neonatal early and late onset sepsis, a retrospective study from the tertiary referral children’s hospital. Infect Drug Resist 16:4213–4225

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mariani M, Parodi A, Minghetti D et al (2022) Early and late onset neonatal sepsis: epidemiology and effectiveness of empirical antibacterial therapy in a III level neonatal intensive care unit. Antibiotics (Basel) 11(2):284

Article  CAS  PubMed  Google Scholar 

Shariati A, Dadashi M, Moghadam MT et al (2020) Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical isolates: a systematic review and meta-analysis. Sci Rep 10(1):12689

Article  CAS  PubMed  PubMed Central  Google Scholar 

Belete MA, Gedefie A, Alemayehu E et al (2023) The prevalence of vancomycin-resistant Staphylococcus aureus in Ethiopia: a systematic review and meta-analysis. Antimicrob Resist Infect Control 12(1):86

Article  PubMed  PubMed Central  Google Scholar 

Bandín-Vilar E, García-Quintanilla L, Castro-Balado A et al (2022) Review of population pharmacokinetic analyses of linezolid. Clin Pharmacokinet 61(6):789–817

Article  PubMed  PubMed Central  Google Scholar 

Linezolid. In: Lexicomp Online (2023) Pediatric & Neonatal Lexi-Drugs. Hudson, OH: Lexi-Comp, Inc. Available from: www.online.lexi.com. Accessed 15 Jan 2023

Matrat L, Plaisant F, Barreto C et al (2020) Increasing use of linezolid in a tertiary NICU during a 10-year period: reasons and concerns for the future. Antimicrob Resist Infect Control 9(1):156

Article  PubMed  PubMed Central  Google Scholar 

Buccellato E, Melis M, Biagi C et al (2015) Use of antibiotics in pediatrics: 8-year survey in Italian hospitals. PLoS ONE 10:e0139097

Article  PubMed  PubMed Central  Google Scholar 

Bagga B, Buckingham S, Arnold S et al (2018) Increasing linezolid-resistant enterococcus in a children’s hospital. Pediatr Infect Dis J 37:242–244

Article  PubMed  Google Scholar 

Hallam MJ, Allen JM, James SE et al (2010) Potential subtherapeutic linezolid and meropenem antibiotic concentrations in a patient with severe burns and sepsis. J Burn Care Res 31:207–209

Article  PubMed  Google Scholar 

El-Gaml RM, El-Khodary NM, Abozahra RR et al (2022) Applying pharmacokinetic/pharmacodynamic measurements for linezolid in critically ill patients: optimizing efficacy and reducing resistance occurrence. Eur J Clin Pharmacol 78(8):1301–1310

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dong H, Wang X, Dong Y et al (2011) Clinical pharmacokinetic/pharmacodynamic profile of linezolid in severely ill intensive care unit patients. Int J Antimicrob Agents 38:296–300

Article  CAS  PubMed  Google Scholar 

Galar A, Valerio M, Muñoz P et al (2017) Systematic therapeutic drug monitoring for linezolid: variability and clinical impact. Antimicrob Agents Chemother 61(10):e00687-e717

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gandelman K, Zhu T, Fahmi OA et al (2011) Unexpected effect of rifampin on the pharmacokinetics of linezolid: in silico and in vitro approaches to explain its mechanism. J Clin Pharmacol 51:229–236

Article  CAS  PubMed  Google Scholar 

Bolhuis MS, van Altena R, Uges DR et al (2010) Clarithromycin significantly increases linezolid serum concentrations. Antimicrob Agents Chemother 54:5418–5419

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pea F, Viale P, Cojutti P et al (2012) Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients. J Antimicrob Chemother 67(8):2034–2042

Article  CAS  PubMed  Google Scholar 

Rao GG, Konicki R, Cattaneo D et al (2020) Therapeutic drug monitoring can improve linezolid dosing regimens in current clinical practice: a review of linezolid pharmacokinetics and pharmacodynamics. Ther Drug Monit 42(1):83–92

Article  PubMed  Google Scholar 

Lau C, Marriott D, Bui J et al (2023) LInezolid Monitoring to MInimise Toxicity (LIMMIT1): a multicentre retrospective review of patients receiving linezolid therapy and the impact of therapeutic drug monitoring. Int J Antimicrob Agents 61(5):106783

Article  CAS  PubMed  Google Scholar 

Cojutti P, Maximova N, Crichiutti G et al (2015) Pharmacokinetic/pharmacodynamic evaluation of linezolid in hospitalized paediatric patients: a step toward dose optimization by means of therapeutic drug monitoring and Monte Carlo simulation. J Antimicrob Chemother 70(1):198–206

Article  CAS  PubMed  Google Scholar 

Lin B, Hu Y, Xu P et al (2022) Expert consensus statement on therapeutic drug monitoring and individualization of linezolid. Front Public Health 10:967311

Article  PubMed  PubMed Central  Google Scholar 

Alsultan A (2019) Determining therapeutic trough ranges for linezolid. Saudi Pharm J 27(8):1061–1063

Article  CAS  PubMed  PubMed Central  Google Scholar 

FDA (2023) Linezolid prescribing information. U.S. Food and Drug Administration. Accessed 15 Jun 2023.

Han X, Wang J, Zan X et al (2022) Risk factors for linezolid-induced thrombocytopenia in adult inpatients. Int J Clin Pharm 44(2):330–338

Article  CAS  PubMed  Google Scholar 

Kaya Kılıç E, Bulut C, Sönmezer MÇ et al (2019) Risk factors for linezolid-associated thrombocytopenia and negative effect of carbapenem combination. J Infect Dev Ctries 13(10):886–891

Article  PubMed  Google Scholar 

Shi Y, Wu HL, Wu YH et al (2023) Safety and clinical efficacy of linezolid in children: a systematic review and meta-analysis. World J Pediatr 19(2):129–138

Article  CAS  PubMed  Google Scholar 

Kato H, Hagihara M, Asai N et al (2021) A systematic review and meta-analysis of myelosuppression in pediatric patients treated with linezolid for Gram-positive bacterial infections. J Infect Chemother 27(8):1143–1150

Article  CAS  PubMed